Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

473 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival of Women Previously Diagnosed of Melanoma with Subsequent Pregnancy: A Systematic Review and Meta-Analysis and a Single-Center Experience.
Martínez-Campayo N, Paradela de la Morena S, Pértega-Díaz S, Iglesias Pena L, Vihinen P, Mattila K, Lens MB, Tejera-Vaquerizo A, Fonseca E. Martínez-Campayo N, et al. Among authors: mattila k. J Clin Med. 2021 Dec 24;11(1):83. doi: 10.3390/jcm11010083. J Clin Med. 2021. PMID: 35011822 Free PMC article. Review.
Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.
Mattila KE, Vihinen P, Ramadan S, Skyttä T, Tiainen L, Vuoristo MS, Tyynelä-Korhonen K, Koivunen J, Kohtamäki L, Mäkelä S, Hernberg M. Mattila KE, et al. Acta Oncol. 2020 Mar;59(3):310-314. doi: 10.1080/0284186X.2019.1670862. Epub 2019 Sep 28. Acta Oncol. 2020. PMID: 31564175 No abstract available.
Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.
Mattila KE, Mäkelä S, Kytölä S, Andersson E, Vihinen P, Ramadan S, Skyttä T, Tiainen L, Vuoristo MS, Tyynelä-Korhonen K, Koivunen J, Kohtamäki L, Aittomäki K, Hernberg M. Mattila KE, et al. Acta Oncol. 2022 Oct;61(10):1263-1267. doi: 10.1080/0284186X.2022.2137693. Epub 2022 Oct 28. Acta Oncol. 2022. PMID: 36307938 Clinical Trial.
Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy.
Vihinen H, Jokinen A, Laajala TD, Wahid N, Peltola L, Kettunen T, Rönkä A, Tiainen L, Skyttä T, Kohtamäki L, Tulokas S, Karhapää H, Hernberg M, Silvoniemi M, Mattila KE. Vihinen H, et al. Clin Lung Cancer. 2023 Jun;24(4):295-304. doi: 10.1016/j.cllc.2023.01.004. Epub 2023 Jan 24. Clin Lung Cancer. 2023. PMID: 36774235 Free article.
473 results